2023-01-012023-12-312023-12-31false08941985MARKS TEY HEALTHCARE LIMITED2024-09-2447730iso4217:GBPxbrli:pure089419852023-01-01089419852023-12-31089419852023-01-012023-12-31089419852022-01-01089419852022-12-31089419852022-01-012022-12-3108941985bus:SmallEntities2023-01-012023-12-3108941985bus:AuditExempt-NoAccountantsReport2023-01-012023-12-3108941985bus:FullAccounts2023-01-012023-12-3108941985bus:PrivateLimitedCompanyLtd2023-01-012023-12-3108941985core:WithinOneYear2023-12-3108941985core:AfterOneYear2023-12-3108941985core:WithinOneYear2022-12-3108941985core:AfterOneYear2022-12-3108941985core:ShareCapital2023-12-3108941985core:SharePremium2023-12-3108941985core:RevaluationReserve2023-12-3108941985core:OtherReservesSubtotal2023-12-3108941985core:RetainedEarningsAccumulatedLosses2023-12-3108941985core:ShareCapital2022-12-3108941985core:SharePremium2022-12-3108941985core:RevaluationReserve2022-12-3108941985core:OtherReservesSubtotal2022-12-3108941985core:RetainedEarningsAccumulatedLosses2022-12-3108941985core:LandBuildings2023-12-3108941985core:PlantMachinery2023-12-3108941985core:Vehicles2023-12-3108941985core:FurnitureFittings2023-12-3108941985core:OfficeEquipment2023-12-3108941985core:NetGoodwill2023-12-3108941985core:IntangibleAssetsOtherThanGoodwill2023-12-3108941985core:ListedExchangeTraded2023-12-3108941985core:UnlistedNon-exchangeTraded2023-12-3108941985core:LandBuildings2022-12-3108941985core:PlantMachinery2022-12-3108941985core:Vehicles2022-12-3108941985core:FurnitureFittings2022-12-3108941985core:OfficeEquipment2022-12-3108941985core:NetGoodwill2022-12-3108941985core:IntangibleAssetsOtherThanGoodwill2022-12-3108941985core:ListedExchangeTraded2022-12-3108941985core:UnlistedNon-exchangeTraded2022-12-3108941985core:LandBuildings2023-01-012023-12-3108941985core:PlantMachinery2023-01-012023-12-3108941985core:Vehicles2023-01-012023-12-3108941985core:FurnitureFittings2023-01-012023-12-3108941985core:OfficeEquipment2023-01-012023-12-3108941985core:NetGoodwill2023-01-012023-12-3108941985core:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-3108941985core:ListedExchangeTraded2023-01-012023-12-3108941985core:UnlistedNon-exchangeTraded2023-01-012023-12-3108941985core:MoreThanFiveYears2023-01-012023-12-3108941985core:Non-currentFinancialInstruments2023-12-3108941985core:Non-currentFinancialInstruments2022-12-3108941985dpl:CostSales2023-01-012023-12-3108941985dpl:DistributionCosts2023-01-012023-12-3108941985core:LandBuildings2023-01-012023-12-3108941985core:PlantMachinery2023-01-012023-12-3108941985core:Vehicles2023-01-012023-12-3108941985core:FurnitureFittings2023-01-012023-12-3108941985core:OfficeEquipment2023-01-012023-12-3108941985dpl:AdministrativeExpenses2023-01-012023-12-3108941985core:NetGoodwill2023-01-012023-12-3108941985core:IntangibleAssetsOtherThanGoodwill2023-01-012023-12-3108941985dpl:GroupUndertakings2023-01-012023-12-3108941985dpl:ParticipatingInterests2023-01-012023-12-3108941985dpl:GroupUndertakingscore:ListedExchangeTraded2023-01-012023-12-3108941985core:ListedExchangeTraded2023-01-012023-12-3108941985dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-01-012023-12-3108941985core:UnlistedNon-exchangeTraded2023-01-012023-12-3108941985dpl:CostSales2022-01-012022-12-3108941985dpl:DistributionCosts2022-01-012022-12-3108941985core:LandBuildings2022-01-012022-12-3108941985core:PlantMachinery2022-01-012022-12-3108941985core:Vehicles2022-01-012022-12-3108941985core:FurnitureFittings2022-01-012022-12-3108941985core:OfficeEquipment2022-01-012022-12-3108941985dpl:AdministrativeExpenses2022-01-012022-12-3108941985core:NetGoodwill2022-01-012022-12-3108941985core:IntangibleAssetsOtherThanGoodwill2022-01-012022-12-3108941985dpl:GroupUndertakings2022-01-012022-12-3108941985dpl:ParticipatingInterests2022-01-012022-12-3108941985dpl:GroupUndertakingscore:ListedExchangeTraded2022-01-012022-12-3108941985core:ListedExchangeTraded2022-01-012022-12-3108941985dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-01-012022-12-3108941985core:UnlistedNon-exchangeTraded2022-01-012022-12-3108941985core:NetGoodwill2023-12-3108941985core:IntangibleAssetsOtherThanGoodwill2023-12-3108941985core:LandBuildings2023-12-3108941985core:PlantMachinery2023-12-3108941985core:Vehicles2023-12-3108941985core:FurnitureFittings2023-12-3108941985core:OfficeEquipment2023-12-3108941985core:AfterOneYear2023-12-3108941985core:WithinOneYear2023-12-3108941985core:ListedExchangeTraded2023-12-3108941985core:UnlistedNon-exchangeTraded2023-12-3108941985core:ShareCapital2023-12-3108941985core:SharePremium2023-12-3108941985core:RevaluationReserve2023-12-3108941985core:OtherReservesSubtotal2023-12-3108941985core:RetainedEarningsAccumulatedLosses2023-12-3108941985core:NetGoodwill2022-12-3108941985core:IntangibleAssetsOtherThanGoodwill2022-12-3108941985core:LandBuildings2022-12-3108941985core:PlantMachinery2022-12-3108941985core:Vehicles2022-12-3108941985core:FurnitureFittings2022-12-3108941985core:OfficeEquipment2022-12-3108941985core:AfterOneYear2022-12-3108941985core:WithinOneYear2022-12-3108941985core:ListedExchangeTraded2022-12-3108941985core:UnlistedNon-exchangeTraded2022-12-3108941985core:ShareCapital2022-12-3108941985core:SharePremium2022-12-3108941985core:RevaluationReserve2022-12-3108941985core:OtherReservesSubtotal2022-12-3108941985core:RetainedEarningsAccumulatedLosses2022-12-3108941985core:NetGoodwill2022-01-0108941985core:IntangibleAssetsOtherThanGoodwill2022-01-0108941985core:LandBuildings2022-01-0108941985core:PlantMachinery2022-01-0108941985core:Vehicles2022-01-0108941985core:FurnitureFittings2022-01-0108941985core:OfficeEquipment2022-01-0108941985core:AfterOneYear2022-01-0108941985core:WithinOneYear2022-01-0108941985core:ListedExchangeTraded2022-01-0108941985core:UnlistedNon-exchangeTraded2022-01-0108941985core:ShareCapital2022-01-0108941985core:SharePremium2022-01-0108941985core:RevaluationReserve2022-01-0108941985core:OtherReservesSubtotal2022-01-0108941985core:RetainedEarningsAccumulatedLosses2022-01-0108941985core:AfterOneYear2023-01-012023-12-3108941985core:WithinOneYear2023-01-012023-12-3108941985core:Non-currentFinancialInstrumentscore:CostValuation2023-01-012023-12-3108941985core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-01-012023-12-3108941985core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-01-012023-12-3108941985core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-01-012023-12-3108941985core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-01-012023-12-3108941985core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-01-012023-12-3108941985core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-01-012023-12-3108941985core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-01-012023-12-3108941985core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-01-012023-12-3108941985core:Non-currentFinancialInstrumentscore:CostValuation2023-12-3108941985core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-12-3108941985core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-12-3108941985core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-12-3108941985core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-12-3108941985core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-12-3108941985core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-12-3108941985core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-12-3108941985core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-12-3108941985core:Non-currentFinancialInstrumentscore:CostValuation2022-12-3108941985core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-12-3108941985core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-12-3108941985core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-12-3108941985core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-12-3108941985core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-12-3108941985core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-12-3108941985core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-12-3108941985core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-12-3108941985bus:Director12023-01-012023-12-31

MARKS TEY HEALTHCARE LIMITED

Registered Number
08941985
(England and Wales)

Unaudited Financial Statements for the Year ended
31 December 2023

MARKS TEY HEALTHCARE LIMITED
Company Information
for the year from 1 January 2023 to 31 December 2023

Director

OSORIO RODRIGUEZ, Jose

Registered Address

89 London Road
Marks Tey
Colchester
CO6 1EB

Registered Number

08941985 (England and Wales)
MARKS TEY HEALTHCARE LIMITED
Balance Sheet as at
31 December 2023

Notes

2023

2022

£

£

£

£

Fixed assets
Investments3599,305599,305
599,305599,305
Current assets
Cash at bank and on hand22,277-
22,277-
Creditors amounts falling due within one year4(271,185)(214,569)
Net current assets (liabilities)(248,908)(214,569)
Total assets less current liabilities350,397384,736
Creditors amounts falling due after one year5(128,965)(150,739)
Net assets221,432233,997
Capital and reserves
Called up share capital100100
Profit and loss account221,332233,897
Shareholders' funds221,432233,997
The financial statements were approved and authorised for issue by the Director on 24 September 2024, and are signed on its behalf by:
OSORIO RODRIGUEZ, Jose
Director
Registered Company No. 08941985
MARKS TEY HEALTHCARE LIMITED
Notes to the Financial Statements
for the year ended 31 December 2023

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Revenue from sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Investments
Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value where the difference between cost and fair value is material. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.
2.Average number of employees

20232022
Average number of employees during the year00
3.Fixed asset investments

Investments in groups1

Total

££
Cost or valuation
At 01 January 23599,305599,305
At 31 December 23599,305599,305
Net book value
At 31 December 23599,305599,305
At 31 December 22599,305599,305

Notes

1Investments in group undertakings and participating interests
4.Creditors: amounts due within one year

2023

2022

££
Bank borrowings and overdrafts29,55929,670
Amounts owed to related parties136,27450,547
Other creditors105,352134,352
Total271,185214,569
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
5.Creditors: amounts due after one year

2023

2022

££
Bank borrowings and overdrafts128,965150,739
Total128,965150,739
6.Related party transactions
At the yearend, the company owed £136,274 (2022: £50,547) to Marks Tey Pharmacy Ltd. The companies are related as Marks Tey Healthcare Ltd owns 100% share capital of Marks Tey Pharmacy Ltd.